Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 21 for “"Thiazolidinediones"”.
-
Market Response to Food and Drug Administration's Safety Warnings: a Case Study Using an Interrupted Time Series Analysis of the Medicare Database for 2006-2008
… 2008. Beneficiaries with Part D claims for thiazolidinediones were classified into appropriate-use, at risk, and contraindicated groups based on certain comorbid conditions. We assessed the effects of the May 2007 FDA safety warning about an ongoing safety review of rosiglitazone's potential …
-
Investigation of potential intervention targets to improve insulin action: a therapeutic approach
… sensitivity, e.g. metformin, tolbutamide, thiazolidinediones, vanadyl sulphate and thioctic acid. Models used for investigation included the L6 skeletal muscle cell line and isolated skeletal muscles. In vivo studies were undertaken to investigate glycaemia, insulinaemia, satiety and body …
-
Deciphering the mechanism of foxa2 inactivation by respiratory pathogens in chronically diseased lungs
… we showed that both incretin mimetics and thiazolidinediones drugs, prescribed to diabetes mellitus 2 patients, are strong agonists of FOXA2, by activating the glucagon-like peptide-1 receptor (GLP-1R)-mediated signaling that normalizes mucin expression and improved the clearance of P. …
-
The effect of metformin on vascular function and AMP-activated protein kinase activation in Type 2 diabetes
… link are incompletely understood. Biguanides and thiazolidinediones are widely used in the treatment of Type 2 diabetes to improve glycaemia but the precise site, mode and extent of their actions remain uncertain. For example, in the United Kingdom Prospective Diabetes Study (UKPDS), metformin …
-
Defining Novel Clusters of PPAR gamma Partial Agonists for Virtual Screening
… including type 2 diabetes mellitus (T2D). Thiazolidinediones (TZDs) are agonists of PPARγ which have an insulin sensitizing effect, and are therefore used as a treatment for T2D. However, TZDs cause negative side effects in patients, such as weight gain, edema, and increased risk of bone …
-
Abscisic acid ameliorates glucose tolerance and obesity-induced inflammation
… treatment of insulin resistance have been the thiazolidinediones (TZDs), which act through the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma ). Due to the many side-effects of TZDs, our laboratory sought out a natural phytochemical, abscisic acid (ABA), with …
-
Mechanisms underlying lipotoxicity and glucotoxicity in pancreatic islets
… is counteracted by ROZ at GPR40, suggesting the thiazolidinediones are protective against beta-cell lipotoxicity.
-
Investigation of the function, pharmacology and oligomerisation of GPR40, GPR41 and GPR43
… This also allowed the potency of a variety of thiazolidinediones and small molecule agonists to be determined. It was found that troglitazone was the most potent thiazolidinedione tested. Rosiglitazone also acted as an agonist of GPR40, albeit with lower potency than troglitazone, whereas …
-
Assessment and Treatment of Impaired Insulin- Secretion and Action in Type 2 Diabetes
… use in clinical practice. The introduction of thiazolidinediones (TZDs) targeting the insulin resistance component of T2D has been promising but accompanied with some adverse effects, mainly fluid retention and heart failure. In this thesis, a simple method for independent measurement of β-cell …
-
Pharmacological modulation of insulin resistance - benefits and harms
Aims: Thiazolidinediones have been advocated as second or third line insulin sensitizing agents in the management of type 2 diabetes (T2DM). Their widespread use has been hampered by concerns about their cardiovascular safety, including fluid retention. Metformin is established as first-line …
-
Neuroprotective and immunomodulatory properties of the new PPARγ agonist MDG548: an in vitro and in vivo study in PD models
… concerns have been raised about PPARγ agonists thiazolidinediones (TZD) currently available, prompting for the development of non-TZD compounds. Aim of this study was to characterize a novel PPARγ agonist non TZD, MDG548, for its potential neuroprotective effect in PD models and its …
-
Regulation of PPARgamma Activity by mTOR in Adipogenesis
… and insulin signals, respectively. A thiazolidinediones drug troglitazone was found to reverse the inhibitory effects of both rapamycin and amino acid deprivation, implicating therapeutic value of these drugs to counter side effects of rapamycin as an immunosuppressant. A potential …
-
Functional genomic analysis of PPAR-gamma in human colorectal cancer cells
… colorectal cancer. Activation of PPAR-gamma by thiazolidinediones (TZDs) inhibits proliferation and induces differentiation in human colon cancer cells. RS5444, a novel TZD, is a high affinity and high specificity ligand for PPAR-gamma. We have shown that RS5444 markedly reduced the …
-
Insulin resistance, chronic heart failure and potential treatment
… certain insulin sensitizers, most notably, the thiazolidinediones (TZDs), which has been linked with increased risk of hospitalizations for CHF and concerns regarding its association with increased myocardial infarction. Despite previous concerns of lactic acidosis, there is now evidence that …
-
Metabolic Regulation by Fibroblast Growth Factor 21
… anti-diabetic properties of PPARg agonists (ie. thiazolidinediones), diet-induced obese wild type and Fgf21-/- mice were treated with the TZD rosiglitazone. Rosiglitazone produced a significant increase in adipose FGF21 expression, but decreased hepatic FGF21 mRNA and circulating FGF21 protein. …
-
Genetic and non-genetic determinants of drug response in type 2 diabetes
… proteins withHbA1c reduction and weight gain to thiazolidinediones (TZDs), we showed a largeclinical impact on the therapeutic response to rosiglitazone. Lastly, in a meta-analysis consisting of 1,235T2D subjects treated with GLP-1RAs, carriers of two or more variant allelesderived from …
-
Cardiovascular Effects of GLP-1 and Glucagon Dual Receptor Agonism in Humans
… with weight gain (insulin, sulphonylureas and thiazolidinediones) or an increased risk of hypoglycaemia (insulin and sulfonylureas). A wealth of new anti-diabetic agents have emerged over the past two decades including dipeptidyl peptidase IV inhibitors, glucagon like peptide-1 (GLP-1) receptor …
-
Glycemic control and pancreatic beta cells protective effect of a lanosteryl triterpene from Protorhus longifolia in hyperlipidemic and STZ-induced diabetic rats
… drugs such as biguanides (metformin), thiazolidinediones and sulfonylureas. Metformin is currently the most commonly used antidiabetic drug. However, due to the lack of compliance to self-care recommendations and some undesirable side effects of metformin, there is an increasing need …
-
Determinação Quantitativa de um Derivado Tiazolidínico (3-(2-bromo-benzil)-5-(5-bromo-2-metoxi-benzilideno)-tiazolidina-2,4-diona) em Plasma de Ratos Wistar: Desenvolvimento e Validação de um Método Analítico Recife
Dentre vários compostos sintetizados pelo Laboratório de Planejamento e Síntese de Fármacos (LPSF) da Universidade Federal de Pernambuco, o derivado tiazolidínico (3-(2-Bromo-benzil)-5-(5-bromo-2-metoxi-benzilideno)-tiazolidina-2,4-diona) (LPSF/GQ-113B) apresentou importante atividade …
Page 1 of 2